Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06493578 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
A Phase 2 study of Non-segmental Vitiligo, sponsored by Vyne Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06493578 is a Phase 2 study of Non-segmental Vitiligo that is active but no longer recruiting, run by Vyne Therapeutics. The registered enrollment target is 200 participants, roughly in line with the 186-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target. The trial reports 20 study locations across 6 states.
The verdict
NCT06493578, a Phase 2 study of Non-segmental Vitiligo, is active but no longer recruiting, sponsored by Vyne Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
Conditions Studied
Interventions
- DRUG VYN201 Gel
- DRUG Vehicle Gel
Study Locations (20)
California
- California Dermatology & Clinical Research Institute - Encinitas
- First OC Dermatology Research, Inc - Fountain Valley
- Center for Dermatology Clinical Research, Inc - Fremont
- Marvel Clinical Research - Huntington Beach
- Northridge Clinical Trials - Northridge
- Palmtree Clinical Research, Inc. - Palm Springs
- Integrative Skin Science and Research - Sacramento
Florida
- Skin Care Research - Boca Raton
- Driven Research LLC - Coral Gables
- Skin Care Research - Hollywood
- International Clinical Research - FL LLC - Sanford
- Metabolic Research Institute, Inc - West Palm Beach
Arizona
- Saguaro Dermatology - Phoenix
- Center for Dermatology and Plastic Surgery/CCT Research - Scottsdale
- Noble Clinical Research - Tucson
Arkansas
- Clinical Trial Institute of Northwest Arkansas, LLC - Fayetteville
- Burke Pharmaceutical Research - Hot Springs
Colorado
- Clarity Dermatology - Castle Rock
- Colorado Medical Research Center - Denver
Alabama
- Cahaba Dermatology & Skin Health Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06493578
The ClinicalTrials.gov registry entry for NCT06493578 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 186-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which VYN201 Gel is the first listed.
NCT06493578 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06493578 about?
NCT06493578 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.". The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
What is the current status of trial NCT06493578?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-06-04. Estimated completion is 2026-01-30.
What conditions does trial NCT06493578 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT06493578?
The interventions under investigation include: VYN201 Gel (DRUG), Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT06493578?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06493578 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
COMPLETED · Phase 2
-
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.